Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:botulism
|
| gptkbp:administered_by |
injection
|
| gptkbp:approves |
gptkb:2009
gptkb:FDA |
| gptkbp:available_on |
prescription medication
|
| gptkbp:brand |
gptkb:Dysport
|
| gptkbp:chemical_formula |
C1766 H2934 N508 O600 S8
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:clinical_use |
neurology
dermatology pain management aesthetic medicine |
| gptkbp:contraindication |
pregnancy
allergy to botulinum toxin |
| gptkbp:dosage_form |
gptkb:liquid
|
| gptkbp:financial_stability |
limited shelf life
|
| gptkbp:formulation |
lyophilized powder
|
| https://www.w3.org/2000/01/rdf-schema#label |
abobotulinumtoxin A
|
| gptkbp:indication |
spasticity
chronic migraine glabellar lines blepharospasm cervical dystonia |
| gptkbp:influenced_by |
clinical studies
patient feedback regulatory approvals |
| gptkbp:interacts_with |
muscle relaxants
aminoglycoside antibiotics |
| gptkbp:invention |
2024
patented |
| gptkbp:is_monitored_by |
recommended post-injection monitoring
|
| gptkbp:marketed_as |
gptkb:Dysport
multiple countries |
| gptkbp:mechanism_of_action |
gptkb:Poison
|
| gptkbp:produced_by |
gptkb:Allergan
|
| gptkbp:provides_guidance_on |
follow established protocols
|
| gptkbp:recommissioned |
requires sterile saline
|
| gptkbp:related_to |
gptkb:botulism
|
| gptkbp:research_areas |
cosmetic dermatology
therapeutic botulinum toxin applications |
| gptkbp:route_of_administration |
intramuscular
aseptic technique recommended |
| gptkbp:safety_features |
generally safe when used correctly
|
| gptkbp:service_frequency |
every 3-6 months
|
| gptkbp:side_effect |
headache
muscle weakness dry mouth pain at injection site rare allergic reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:used_for |
cosmetic procedures
treatment of muscle spasms treatment of excessive sweating |
| gptkbp:weight |
150 k Da
|
| gptkbp:bfsParent |
gptkb:Dysport
|
| gptkbp:bfsLayer |
7
|